Advanced search
1 file | 588.33 KB Add to list

Scheduled maintenance: Publication downloads temporarily unavailable.

Due to maintenance publication downloads will not be available on:

  • Wednesday, March 27, 17:00 – 21:00
  • Thursday, March 28, 17:00 – 21:00

Exports of lists, FWO and BOF information will remain available.

For any questions, please contact biblio@ugent.be. Apologies for any inconveniences, and thank you for your understanding.

Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults

(2008) VACCINE. 26(51). p.6614-6619
Author
Organization
Abstract
Influenza vaccines remain largely underused. A promising alternative to Current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination. A phase 11, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV. Subjects received a 0.1 ml injection of intradermal TIV, containing 9 mu g of haemagglutinin (HA) per strain (it = 588) or a conventional 0.5 ml intramuscular vaccine (15 mu g of HA/strain: n = 390). Intradermal,11 TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated. (C) 2008 Elsevier Ltd. All rights reserved.
Keywords
DENDRITIC CELLS, HEPATITIS-B, RABIES VACCINATION, Haemagglutination inhibition, ANTIBODY-RESPONSES, Immune response, Microinjection, Influenza vaccine, Intradermal, IMMUNIZATION, BELIEFS, SYSTEM

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 588.33 KB

Citation

Please use this url to cite or link to this publication:

MLA
Leroux-Roels, Isabel, et al. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE, vol. 26, no. 51, ELSEVIER SCI LTD, 2008, pp. 6614–19, doi:10.1016/j.vaccine.2008.09.078.
APA
Leroux-Roels, I., Vets, E., Freese, R., Seiberling, M., Weber, F., Salamand, C., & Leroux-Roels, G. (2008). Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. VACCINE, 26(51), 6614–6619. https://doi.org/10.1016/j.vaccine.2008.09.078
Chicago author-date
Leroux-Roels, Isabel, Eva Vets, Ralf Freese, Michael Seiberling, Francoise Weber, Camille Salamand, and Geert Leroux-Roels. 2008. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE 26 (51): 6614–19. https://doi.org/10.1016/j.vaccine.2008.09.078.
Chicago author-date (all authors)
Leroux-Roels, Isabel, Eva Vets, Ralf Freese, Michael Seiberling, Francoise Weber, Camille Salamand, and Geert Leroux-Roels. 2008. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE 26 (51): 6614–6619. doi:10.1016/j.vaccine.2008.09.078.
Vancouver
1.
Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. VACCINE. 2008;26(51):6614–9.
IEEE
[1]
I. Leroux-Roels et al., “Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults,” VACCINE, vol. 26, no. 51, pp. 6614–6619, 2008.
@article{597785,
  abstract     = {{Influenza vaccines remain largely underused. A promising alternative to Current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination. A phase 11, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV. Subjects received a 0.1 ml injection of intradermal TIV, containing 9 mu g of haemagglutinin (HA) per strain (it = 588) or a conventional 0.5 ml intramuscular vaccine (15 mu g of HA/strain: n = 390). Intradermal,11 TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated. (C) 2008 Elsevier Ltd. All rights reserved.}},
  author       = {{Leroux-Roels, Isabel and Vets, Eva and Freese, Ralf and Seiberling, Michael and Weber, Francoise and Salamand, Camille and Leroux-Roels, Geert}},
  issn         = {{0264-410X}},
  journal      = {{VACCINE}},
  keywords     = {{DENDRITIC CELLS,HEPATITIS-B,RABIES VACCINATION,Haemagglutination inhibition,ANTIBODY-RESPONSES,Immune response,Microinjection,Influenza vaccine,Intradermal,IMMUNIZATION,BELIEFS,SYSTEM}},
  language     = {{eng}},
  number       = {{51}},
  pages        = {{6614--6619}},
  publisher    = {{ELSEVIER SCI LTD,}},
  title        = {{Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults}},
  url          = {{http://doi.org/10.1016/j.vaccine.2008.09.078}},
  volume       = {{26}},
  year         = {{2008}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: